R&D News | pharmaphorum

News

JPM kicks off with takeovers by J&J, Novartis, and MSD

The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD.

News

Servier will apply ‘digital twin’ tech to Parkinson’s drug

French pharma Servier has enlisted the aid of ‘digital twin’ specialist Aitia for a third time, adding a Parkinson’s disease project to their prior collaborations on pancr

News

Rumour mill says MSD is hunting Harpoon Therapeutics

MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeuti

News

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma pa

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

News

Click bags FDA breakthrough tag for schizophrenia DTx

Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia

JPM kicks off with takeovers by J&J, Novartis, and MSD

Servier will apply ‘digital twin’ tech to Parkinson’s drug

Rumour mill says MSD is hunting Harpoon Therapeutics

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

atai invests $50m in Beckley Psytech

Click bags FDA breakthrough tag for schizophrenia DTx

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks